A novel TRP channel-related prognostic model of glioma based on transcriptomics and single cell sequencing analysis

Glioma is the most malignant intracranial tumor. Transient receptor potential (TRP) channel family has been found to be involved in malignant progression of many tumors. However, the relationship between TRP channel-related genes (TCRGs) and glioma remains unclear. Gene expression profiles and clinical data of 1,475 glioma patients were obtained from TCGA, CGGA, and GEO databases. Prognostic TCRGs were screened and used to classify the patients. Lasso Cox regression analysis was used to construct a risk model, which was validated in external cohorts, and the patients were stratified into high- and low-risk groups. Immune infiltration and functional enrichment analyses were performed to explore the tumor microenvironment in two groups, while drug sensitivity predictions were conducted. Single-cell RNA sequencing data were analyzed to examine the cell type-specific expression of key model genes. Finally, RT-qPCR was performed on paired glioma and adjacent normal tissues to validate the expression of all model genes. Thirty-seven differentially expressed TCRGs were identified in glioma, of which 30 were associated with patient survival. Consensus clustering revealed three molecular subtypes with distinct prognoses, immune infiltration, and pathway enrichment. A 10-gene (TRPM6, PRKCB, CAMK2G, ADCY5, HTR2A, P2RY2, MAPK13, BDKRB1, PLA2G4D, and TRPV3) prognostic model stratified patients into high- and low-risk groups with significantly different overall survival, validated in external cohorts. High-risk patients exhibited higher immune cell infiltration and were predicted to be more sensitive to drugs including 5-Fluorouracil, Dasatinib, Gemcitabine, and Rapamycin, whereas low-risk patients were more sensitive to Vorinostat, Lapatinib, Gefitinib, and Osimertinib. Single-cell RNA sequencing showed that TRPV3 was expressed in exhausted CD8+ T cells, supporting the model’s relevance to tumor immunity and patient prognosis. RT-qPCR verification indicated that all 10 genes in the model were expressed at lower levels in glioma tissues. Based on the expression of TCRGs, we conducted the new subtype classification and a prognostic model for glioma, and is expected to provide theoretical basis for the development of new targets.

Authors

Institutions

Publication Details

Journal
Discover Oncology
Published
2025-12-02
DOI
https://doi.org/10.1007/s12672-025-04220-5
Primary Topic
Ion Channels and Receptors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A novel TRP channel-related prognostic model of glioma based on transcriptomics and single cell sequencing analysis

Hongming Ji, Xiaochen Niu, Aijie Guo, Hao Li et al.
Discover Oncology
Ion Channels and Receptors
article

A novel TRP channel-related prognostic model of glioma based on transcriptomics and single cell sequencing analysis

Hongming Ji, Xiaochen Niu, Aijie Guo, Hao Li, Chunhong Wang, Xuanchen Liu
article en

Abstract

Glioma is the most malignant intracranial tumor. Transient receptor potential (TRP) channel family has been found to be involved in malignant progression of many tumors. However, the relationship between TRP channel-related genes (TCRGs) and glioma remains unclear. Gene expression profiles and clinical data of 1,475 glioma patients were obtained from TCGA, CGGA, and GEO databases. Prognostic TCRGs were screened and used to classify the patients. Lasso Cox regression analysis was used to construct a risk model, which was validated in external cohorts, and the patients were stratified into high- and low-risk groups. Immune infiltration and functional enrichment analyses were performed to explore the tumor microenvironment in two groups, while drug sensitivity predictions were conducted. Single-cell RNA sequencing data were analyzed to examine the cell type-specific expression of key model genes. Finally, RT-qPCR was performed on paired glioma and adjacent normal tissues to validate the expression of all model genes. Thirty-seven differentially expressed TCRGs were identified in glioma, of which 30 were associated with patient survival. Consensus clustering revealed three molecular subtypes with distinct prognoses, immune infiltration, and pathway enrichment. A 10-gene (TRPM6, PRKCB, CAMK2G, ADCY5, HTR2A, P2RY2, MAPK13, BDKRB1, PLA2G4D, and TRPV3) prognostic model stratified patients into high- and low-risk groups with significantly different overall survival, validated in external cohorts. High-risk patients exhibited higher immune cell infiltration and were predicted to be more sensitive to drugs including 5-Fluorouracil, Dasatinib, Gemcitabine, and Rapamycin, whereas low-risk patients were more sensitive to Vorinostat, Lapatinib, Gefitinib, and Osimertinib. Single-cell RNA sequencing showed that TRPV3 was expressed in exhausted CD8+ T cells, supporting the model’s relevance to tumor immunity and patient prognosis. RT-qPCR verification indicated that all 10 genes in the model were expressed at lower levels in glioma tissues. Based on the expression of TCRGs, we conducted the new subtype classification and a prognostic model for glioma, and is expected to provide theoretical basis for the development of new targets.

Discover OncologyVol. 17(1)
Shanxi Medical University (CN), Shanxi University (CN), Sichuan University (CN), West China Hospital of Sichuan University (CN), Shanxi Provincial Cancer Hospital (CN), Shanxi Provincial People’s Hospital (CN)
Openalex Percentile: Top 61%
Ion Channels and Receptors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.